Colonial Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$31.8K Buy
106
+3
+3% +$905 ﹤0.01% 593
2026
Q1
$34.2K Buy
103
+4
+4% +$1.36K ﹤0.01% 588
2025
Q4
$39.4K Buy
99
+61
+161% +$27K 0.01% 581
2025
Q3
$17.3K Buy
+38
New +$15.5K ﹤0.01% 693
2025
Q1
Sell
-150
Closed -$35.3K 1100
2024
Q4
$35.3K Buy
+150
New +$39.4K 0.01% 649
2024
Q1
Sell
-2
Closed -$394 986
2023
Q4
$394 Buy
+2
New +$341 ﹤0.01% 950

Other funds holding ALNY

Colonial Trust's ALNY Position: Q2 2026 in Review

Colonial Trust increased its Alnylam Pharmaceuticals (ALNY) stake by 2.9% in Q2 2026, buying an estimated $905 and bringing the position to 106 shares worth $31.8K. The position accounts for ﹤0.01% of the portfolio, ranked #593.

Colonial Trust first reported a position in ALNY in Q4 2023 and has held it in 6 quarters since. The position peaked at $39.4K in Q4 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Colonial Trust held 106 shares of Alnylam Pharmaceuticals worth $31.8K as of Q2 2026.
  • Colonial Trust bought 3 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $905.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Colonial Trust's portfolio in Q2 2026, its #593 holding.
  • Colonial Trust first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
  • Colonial Trust's Alnylam Pharmaceuticals position peaked at $39.4K in Q4 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Colonial Trust's 13F filing for Q2 2026, filed 11 Aug 2026.